US FDA approves Bydureon® Pen (exenatide extended-release for injectable suspension) for once-weekly treatment of adults with type 2 diabetes

[at noodls] – AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved the BYDUREON® Pen (exenatide extended-release for injectable suspension) 2 mg as an adjunct to diet and exercise … more

View todays social media effects on AZN

View the latest stocks trending across Twitter. Click to view dashboard

See who Astrazeneca is hiring next, click here to view